23andMe Inc. closed its C round to raise $22 million from equity-based financing.
The Mountain View, California-based genetics company said the funding came from the Johnson & Johnson Development Corp. (NYSE:JNJ), a new investor, and previous investors including New Enterprise Associates and Google Ventures (NSDQ:GOOG).
Eight unnamed individuals contributed to the round, according to a Securities & Exchange Commission filing, which listed co-founder Linda Avey, co-founder and CEO Anne Wojcicki and board members Esther Dyson and NVA partner Patrick Chung.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
23andMe, which takes its name from the 23 chromosomes that make up human DNA, developed a web-based, personal genetic tool called Personal Genome Service.
“We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research and could ultimately make healthcare research and healthcare delivery more efficient,” Wojcicki said in prepared remarks.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
